Table 1 Characteristics of 93 patients with urothelial bladder carcinoma treated with radical cystecomy and bilateral lymphadenectomy
From: ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
Characteristic | No. (%) |
|---|---|
Total | 93 (100.0) |
Median age (range) | 63 (34 – 79) |
Sex | |
Men | 79 (84.9%) |
Women | 14 (15.1%) |
Pathological T stage | |
T1* | 4 (4.3%) |
T2 | 15 (16.1%) |
T3 | 52 (55.9%) |
T4 | 22 (23.7%) |
Pathological N stage | |
Node negative | 61 (65.6%) |
Node positive | 32 (34.4%) |
Histologic type | |
Squamous differentiation | 11 (11.8%) |
Other types | 82 (88.2%) |
Pathological grade†| |
G2 | 10 (10.8%) |
G3 | 83 (89.2%) |
ERCC1 expression | |
Positive | 54 (58.1%) |
Negative | 39 (41.9%) |
Adjuvant chemotherapy (gemcitabine plus cisplatin) | |
Yes | 57 (61.3%) |
4 cycles | 24 (25.8%) |
3 cycles | 28 (30.1%) |
2 cycles | 4 (4.3%) |
1 cycle | 1 (1.1%) |
No | 36 (38.7%) |